These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 22961090

  • 21. [An exploratory study on in vitro effects and mechanism of leflunomide on dendritic cells of systemic lupus erythematosus].
    Zhang X, Zhou H, Dong GF, Shi YZ.
    Zhonghua Nei Ke Za Zhi; 2005 May; 44(5):370-3. PubMed ID: 16009010
    [Abstract] [Full Text] [Related]

  • 22. Update on the treatment of systemic lupus erythematosus: therapeutic highlights from the Sixth International Lupus Conference.
    Abu-Shakra M, Buskila D.
    Isr Med Assoc J; 2002 Jan; 4(1):71-3. PubMed ID: 11802320
    [Abstract] [Full Text] [Related]

  • 23. Leflunomide: a review of its use in active rheumatoid arthritis.
    Prakash A, Jarvis B.
    Drugs; 1999 Dec; 58(6):1137-64. PubMed ID: 10651393
    [Abstract] [Full Text] [Related]

  • 24. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
    Herrmann ML, Schleyerbach R, Kirschbaum BJ.
    Immunopharmacology; 2000 May; 47(2-3):273-89. PubMed ID: 10878294
    [Abstract] [Full Text] [Related]

  • 25. [Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/antirheumatic drugs; 5. Leflunomide and mizoribine].
    Sawada T.
    Nihon Naika Gakkai Zasshi; 2011 Oct 10; 100(10):2929-35. PubMed ID: 22175133
    [No Abstract] [Full Text] [Related]

  • 26. Lupus erythematosus with leflunomide: induction or reactivation?
    Gensburger D, Kawashima M, Marotte H, Kanitakis J, Miossec P.
    Ann Rheum Dis; 2005 Jan 10; 64(1):153-5. PubMed ID: 15608317
    [Abstract] [Full Text] [Related]

  • 27. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.
    Fragoso YD, Brooks JB.
    Expert Rev Clin Pharmacol; 2015 May 10; 8(3):315-20. PubMed ID: 25712857
    [Abstract] [Full Text] [Related]

  • 28. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial.
    Bao C, Chen S, Gu Y, Lao Z, Ni L, Yu Q, Xu J, Li X, Liu J, Sun L, He P, Ma J, Xu S, Ding C.
    Chin Med J (Engl); 2003 Aug 10; 116(8):1228-34. PubMed ID: 12935395
    [Abstract] [Full Text] [Related]

  • 29. The use of leflunomide in the treatment of rheumatoid arthritis: an experimental and clinical review.
    Schattenkirchner M.
    Immunopharmacology; 2000 May 10; 47(2-3):291-8. PubMed ID: 10878295
    [Abstract] [Full Text] [Related]

  • 30. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study.
    Wang HY, Cui TG, Hou FF, Ni ZH, Chen XM, Lu FM, Xu FF, Yu XQ, Zhang FS, Zhao XZ, Zhao MH, Wang GB, Qian JQ, Cai GY, Zhu TY, Wang YH, Jiang ZP, Li YN, Mei CL, Zou WZ, China Leflunomide Lupus Nephritis Study Group.
    Lupus; 2008 Jul 10; 17(7):638-44. PubMed ID: 18625636
    [Abstract] [Full Text] [Related]

  • 31. Leflunomide in dermatology.
    Boyd AS.
    J Am Acad Dermatol; 2012 Apr 10; 66(4):673-9. PubMed ID: 21962758
    [Abstract] [Full Text] [Related]

  • 32. Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis.
    Bartlett RR, Brendel S, Zielinski T, Schorlemmer HU.
    Transplant Proc; 1996 Dec 10; 28(6):3074-8. PubMed ID: 8962190
    [No Abstract] [Full Text] [Related]

  • 33. Leflunomide for the treatment of rheumatoid arthritis.
    Miceli-Richard C, Dougados M.
    Expert Opin Pharmacother; 2003 Jun 10; 4(6):987-97. PubMed ID: 12783594
    [Abstract] [Full Text] [Related]

  • 34. [Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus].
    Wang L, Yang Y, Jia Y, Miao H, Zhou YS, Zhang XY.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Dec 18; 48(6):1081-1085. PubMed ID: 27987518
    [Abstract] [Full Text] [Related]

  • 35. Leflunomide effectively treats naturally occurring immune-mediated and inflammatory diseases of dogs that are unresponsive to conventional therapy.
    Gregory CR, Stewart A, Sturges B, DeManvelle T, Cannon A, Ortega T, Harb M, Morris RE.
    Transplant Proc; 1998 Dec 18; 30(8):4143-8. PubMed ID: 9865328
    [No Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.
    Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, Loew-Friedrich I, Oed C, Rosenburg R.
    Lancet; 1999 Jan 23; 353(9149):259-66. PubMed ID: 9929017
    [Abstract] [Full Text] [Related]

  • 37. An unusual overdose of leflunomide in a patient with rheumatoid arthritis.
    Kamali S, Kasapoglu E, Uysal M, Inanc M, Gul A.
    Ann Pharmacother; 2004 Jan 23; 38(7-8):1320-1. PubMed ID: 15138298
    [No Abstract] [Full Text] [Related]

  • 38. Leflunomide for the treatment of rheumatoid arthritis and autoimmunity.
    Sanders S, Harisdangkul V.
    Am J Med Sci; 2002 Apr 23; 323(4):190-3. PubMed ID: 12003373
    [Abstract] [Full Text] [Related]

  • 39. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing.
    Alcorn N, Saunders S, Madhok R.
    Drug Saf; 2009 Apr 23; 32(12):1123-34. PubMed ID: 19916579
    [Abstract] [Full Text] [Related]

  • 40. Leflunomide.
    Cohen SB, Iqbal I.
    Int J Clin Pract; 2003 Mar 23; 57(2):115-20. PubMed ID: 12661795
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.